Ultimovacs Q4 2022: Closing in on top-line data - Redeye

Redeye comments on Ultimovacs’ Q4 2022 report, and we judge that INITIUM and NIPU top-line data in H1 2023e will constitute critical catalysts for the company. We believe that solid efficacy results in the coming readouts could provide essential data showing UV1's ability to enhance checkpoint inhibitors’ efficacy.

Länk till analysen i sin helhet: https://www.redeye.se/research/879217/ultimovacs-q4-2022-closing-in-on-top-line-data?utm_source=finwire&utm_medium=RSS